Thursday
Conference/Events
Biopharma Analysts Chen…
Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.
Show Hide Related Items >> <<
03/04/21 VYNE Therapeutics expects cash to fund requirements through end of 2022 03/01/21 VYNE Therapeutics to begin Phase 2a study of FMX114 in Q3 02/11/21 VYNE Therapeutics approves 1-for-4 reverse stock split 02/01/21 VYNE Therapeutics' Amzeeq label update approved by FDA 04/01/21 FDA approves Praluent as on add-on therapy for adult patients with HoFH 03/30/21 NIH trial finds Regeneron's Eylea reduced vision-threatening complications 03/23/21 Regeneron: Phase 3 REGEN-COV trial met primary, secondary endpoints 03/15/21 Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit 03/02/21 BiomX announces dosing of first subject in Phase 2 Study of BX001 for acne 02/02/21 BiomX announces 'positive' results from Phase 1a pharmacokinetic study of BX002 11/04/20 BiomX doses first subject in Phase 1a study of BX002 for inflammatory bowel 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/07/21 Pfizer's NDA for abrocitinib in dermatitis granted extended review by FDA 04/06/21 Cogent Biosciences names John Robinson, PhD as Chief Scientific Officer 04/01/21 Pfizer, BioNTech: Vaccine more than 91% effective after 6 months in study 04/08/21 Eli Lilly, Incyte announce baricitinib study did not meet primary endpoint 04/07/21 Rigel Pharmaceuticals closes R552 licensing agreement with Eli Lilly 04/06/21 Eli Lilly, Incyte announce FDA extension of baricitinib sNDA review period 04/01/21 Fortress Biotech partner Journey Medical to acquire QBREXA from Dermira 04/05/21 Cidara, Janssen enter agreement to develop, commercialize AVCs 04/05/21 J&J assumes responsibility of vaccine manufacturing at Emergent facility 04/05/21 Emergent BioSolutions receives modified $23M task order from BARDA 04/01/21 SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study 03/29/21 Incyte announces European Commission approval of Pemazyre 03/23/21 Incyte reports approval of Pemazyre in Japan for BTC with FGFR2 gene 04/08/21 Bristol-Myers reports 'positive' results from Phase 3 CheckMate -648 trial 04/01/21 Agios Pharmaceuticals enters agreement to repurchase stock from Bristol-Myers 03/30/21 Huyabio International enters clinical collaboration agreement with Bristol-Myers 03/29/21 EMA validates Bristol-Myers' Opdivo application in Muscle-Invasive Carcinoma ARQT Arcutis Biotherapeutics 03/26/21 Arcutis Biotherapeutics announces updates to its executive team 03/18/21 Arcutis Biotherapeutics enrolls first patient in Phase 2a trial of ARQ-252 03/17/21 Arcutis Biotherapeutics to present outcomomes, data, on roflumilast 0.3% cream 02/18/21 Arcutis Biotherapeutics appoints Courtney Barton as CCO, chief of staff ACRS Aclaris Therapeutics 03/15/21 Aclaris Therapeutics completes enrollment in Phase 2a ATI-1777 trial 02/25/21 Aclaris Therapeutics sees cash, equivalents funding operations through 2023E 02/22/21 Aclaris Therapeutics trading resumes 02/22/21 Aclaris Therapeutics trading halted, volatility trading pause 03/24/21 Canaccord Regeneron trial shows positive results against COVID-variants, says Canaccord 03/23/21 Piper Sandler Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler 03/11/21 Evercore ISI Kodiak Sciences initiated with an Outperform at Evercore ISI 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 04/06/21 JPMorgan JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug 03/24/21 BMO Capital AbCellera price target lowered to $59 from $61 at BMO Capital 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho 03/16/21 Mizuho Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab 03/08/21 BofA Gartner added to US 1 List, Bristol-Myers removed at BofA 02/12/21 Morgan Stanley Amgen court decision may have readthrough for Gilead, says Morgan Stanley 02/02/21 BTIG Prothena upgraded to Buy at BTIG on birtamimab 'revival' 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair 04/06/21 RBC Capital Pfizer transferred with a Sector Perform at RBC Capital 02/23/21 B. Riley B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 04/01/21 Piper Sandler Integra to benefit from FDA safety communication, says Piper Sandler 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo ARQT Arcutis Biotherapeutics 02/02/21 Truist Arcutis Biotherapeutics price target raised to $48 from $38 at Truist 02/01/21 Cowen Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen 01/28/21 JonesTrading Arcutis Biotherapeutics initiated with a Buy at JonesTrading 11/09/20 Goldman Sachs Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs 02/10/21 SVB Leerink Incyte downgraded to Market Perform from Outperform at SVB Leerink 01/07/21 Truist Incyte initiated with a Buy at Truist 01/07/21 Truist Incyte initiated with a Buy at Truist 01/04/21 Guggenheim Incyte upgraded to Buy from Neutral at Guggenheim ACRS Aclaris Therapeutics 03/04/21 SVB Leerink Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink 02/02/21 Cantor Fitzgerald Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald 01/19/21 William Blair Aclaris has potential in range of 'blockbuster indications,' says William Blair 02/02/21 H.C. Wainwright BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright 12/07/20 H.C. Wainwright BiomX initiated with a Buy at H.C. Wainwright 10/05/20 H.C. Wainwright VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright 03/04/21 VYNE Therapeutics reports Q4 adjusted EPS (43c) , consensus (53c) 11/05/20 VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 02/09/21 Incyte reports Q4 EPS 93c, consensus 75c 02/08/21 Notable companies reporting before tomorrow's open 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 ARQT Arcutis Biotherapeutics 02/16/21 Arcutis Biotherapeutics reports Q4 EPS (79c), consensus (88c) 11/05/20 Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c) ACRS Aclaris Therapeutics 02/25/21 Aclaris Therapeutics reports Q4 EPS (30c), consensus (27c) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c)
Conference/Events
Biopharma Analysts Chen…
Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.
Show Hide Related Items >> <<
03/04/21 VYNE Therapeutics expects cash to fund requirements through end of 2022 03/01/21 VYNE Therapeutics to begin Phase 2a study of FMX114 in Q3 02/11/21 VYNE Therapeutics approves 1-for-4 reverse stock split 02/01/21 VYNE Therapeutics' Amzeeq label update approved by FDA 04/01/21 FDA approves Praluent as on add-on therapy for adult patients with HoFH 03/30/21 NIH trial finds Regeneron's Eylea reduced vision-threatening complications 03/23/21 Regeneron: Phase 3 REGEN-COV trial met primary, secondary endpoints 03/15/21 Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit 03/02/21 BiomX announces dosing of first subject in Phase 2 Study of BX001 for acne 02/02/21 BiomX announces 'positive' results from Phase 1a pharmacokinetic study of BX002 11/04/20 BiomX doses first subject in Phase 1a study of BX002 for inflammatory bowel 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/07/21 Pfizer's NDA for abrocitinib in dermatitis granted extended review by FDA 04/06/21 Cogent Biosciences names John Robinson, PhD as Chief Scientific Officer 04/01/21 Pfizer, BioNTech: Vaccine more than 91% effective after 6 months in study 04/07/21 Rigel Pharmaceuticals closes R552 licensing agreement with Eli Lilly 04/06/21 Eli Lilly, Incyte announce FDA extension of baricitinib sNDA review period 04/01/21 Fortress Biotech partner Journey Medical to acquire QBREXA from Dermira 03/29/21 Eli Lilly, Vir, GSK announces topline data from Phase 2 BLAZE-4 trial 04/05/21 Cidara, Janssen enter agreement to develop, commercialize AVCs 04/05/21 J&J assumes responsibility of vaccine manufacturing at Emergent facility 04/05/21 Emergent BioSolutions receives modified $23M task order from BARDA 04/01/21 SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study 03/29/21 Incyte announces European Commission approval of Pemazyre 03/23/21 Incyte reports approval of Pemazyre in Japan for BTC with FGFR2 gene 03/18/21 Incyte says DEVENT study of Ruxolitinib did not meet primary endpoint 04/01/21 Agios Pharmaceuticals enters agreement to repurchase stock from Bristol-Myers 03/30/21 Huyabio International enters clinical collaboration agreement with Bristol-Myers 03/29/21 EMA validates Bristol-Myers' Opdivo application in Muscle-Invasive Carcinoma 03/28/21 FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma ARQT Arcutis Biotherapeutics 03/26/21 Arcutis Biotherapeutics announces updates to its executive team 03/18/21 Arcutis Biotherapeutics enrolls first patient in Phase 2a trial of ARQ-252 03/17/21 Arcutis Biotherapeutics to present outcomomes, data, on roflumilast 0.3% cream 02/18/21 Arcutis Biotherapeutics appoints Courtney Barton as CCO, chief of staff ACRS Aclaris Therapeutics 03/15/21 Aclaris Therapeutics completes enrollment in Phase 2a ATI-1777 trial 02/25/21 Aclaris Therapeutics sees cash, equivalents funding operations through 2023E 02/22/21 Aclaris Therapeutics trading resumes 02/22/21 Aclaris Therapeutics trading halted, volatility trading pause 03/24/21 Canaccord Regeneron trial shows positive results against COVID-variants, says Canaccord 03/23/21 Piper Sandler Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler 03/11/21 Evercore ISI Kodiak Sciences initiated with an Outperform at Evercore ISI 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 04/06/21 JPMorgan JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug 03/24/21 BMO Capital AbCellera price target lowered to $59 from $61 at BMO Capital 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho 03/16/21 Mizuho Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab 03/08/21 BofA Gartner added to US 1 List, Bristol-Myers removed at BofA 02/12/21 Morgan Stanley Amgen court decision may have readthrough for Gilead, says Morgan Stanley 02/02/21 BTIG Prothena upgraded to Buy at BTIG on birtamimab 'revival' 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair 04/06/21 RBC Capital Pfizer transferred with a Sector Perform at RBC Capital 02/23/21 B. Riley B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 04/01/21 Piper Sandler Integra to benefit from FDA safety communication, says Piper Sandler 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo ARQT Arcutis Biotherapeutics 02/02/21 Truist Arcutis Biotherapeutics price target raised to $48 from $38 at Truist 02/01/21 Cowen Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen 01/28/21 JonesTrading Arcutis Biotherapeutics initiated with a Buy at JonesTrading 11/09/20 Goldman Sachs Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs 02/10/21 SVB Leerink Incyte downgraded to Market Perform from Outperform at SVB Leerink 01/07/21 Truist Incyte initiated with a Buy at Truist 01/07/21 Truist Incyte initiated with a Buy at Truist 01/04/21 Guggenheim Incyte upgraded to Buy from Neutral at Guggenheim ACRS Aclaris Therapeutics 03/04/21 SVB Leerink Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink 02/02/21 Cantor Fitzgerald Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald 01/19/21 William Blair Aclaris has potential in range of 'blockbuster indications,' says William Blair 02/02/21 H.C. Wainwright BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright 12/07/20 H.C. Wainwright BiomX initiated with a Buy at H.C. Wainwright 10/05/20 H.C. Wainwright VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright 03/04/21 VYNE Therapeutics reports Q4 adjusted EPS (43c) , consensus (53c) 11/05/20 VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 02/09/21 Incyte reports Q4 EPS 93c, consensus 75c 02/08/21 Notable companies reporting before tomorrow's open 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 ARQT Arcutis Biotherapeutics 02/16/21 Arcutis Biotherapeutics reports Q4 EPS (79c), consensus (88c) 11/05/20 Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c) ACRS Aclaris Therapeutics 02/25/21 Aclaris Therapeutics reports Q4 EPS (30c), consensus (27c) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c)
Over a week ago
Conference/Events
Biopharma Analysts Chen…
Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.
Show Hide Related Items >> <<
03/04/21 VYNE Therapeutics expects cash to fund requirements through end of 2022 03/01/21 VYNE Therapeutics to begin Phase 2a study of FMX114 in Q3 02/11/21 VYNE Therapeutics approves 1-for-4 reverse stock split 02/01/21 VYNE Therapeutics' Amzeeq label update approved by FDA 03/23/21 Regeneron: Phase 3 REGEN-COV trial met primary, secondary endpoints 03/15/21 Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit 03/04/21 Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA 03/03/21 Kiniksa jumps 10% to $24 per share after disclosing supply deal with Regeneron 03/02/21 BiomX announces dosing of first subject in Phase 2 Study of BX001 for acne 02/02/21 BiomX announces 'positive' results from Phase 1a pharmacokinetic study of BX002 11/04/20 BiomX doses first subject in Phase 1a study of BX002 for inflammatory bowel 03/29/21 CDC estimates real-world mRNA vaccine effectiveness of 90% at full immunization 03/26/21 BioNTech: EMA approves manufacturing of Covid vaccine at Marburg facility 03/26/21 EMA approves new storage option for Pfizer-BioNTech vaccine 03/25/21 Pfizer says FDA adcom voted 1 for, 19 against on question of REMS for tanezumab 03/29/21 Eli Lilly, Vir, GSK announces topline data from Phase 2 BLAZE-4 trial 03/29/21 Eli Lilly, Vir Biotechnology, GlaxoSmithKline: Positive data from Phase 2 BLAZE 03/21/21 Fly Intel: Top five weekend stock stories 03/17/21 Eli Lilly announces patient-reported outcomes from Verzenio trial 03/29/21 Johnson & Johnson to provide up to 220M COVID-19 vaccine doses to AVAT in Q3 03/28/21 Fly Intel: Top five weekend stock stories 03/26/21 LabCorp appoints Kathryn Wengel to Board of Directors 03/19/21 Janssen announces FDA approval of PONVORY for multiple sclerosis 03/29/21 Incyte announces European Commission approval of Pemazyre 03/23/21 Incyte reports approval of Pemazyre in Japan for BTC with FGFR2 gene 03/18/21 Incyte says DEVENT study of Ruxolitinib did not meet primary endpoint 03/03/21 Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint 03/29/21 EMA validates Bristol-Myers' Opdivo application in Muscle-Invasive Carcinoma 03/28/21 FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma 03/25/21 Bristol-Myers' Celgene gets FDA orphan designation for AML treatment 03/25/21 Bristol-Myers: Follow up for overall survival 'ongoing' ARQT Arcutis Biotherapeutics 03/26/21 Arcutis Biotherapeutics announces updates to its executive team 03/18/21 Arcutis Biotherapeutics enrolls first patient in Phase 2a trial of ARQ-252 03/17/21 Arcutis Biotherapeutics to present outcomomes, data, on roflumilast 0.3% cream 02/18/21 Arcutis Biotherapeutics appoints Courtney Barton as CCO, chief of staff ACRS Aclaris Therapeutics 03/15/21 Aclaris Therapeutics completes enrollment in Phase 2a ATI-1777 trial 02/25/21 Aclaris Therapeutics sees cash, equivalents funding operations through 2023E 02/22/21 Aclaris Therapeutics trading resumes 02/22/21 Aclaris Therapeutics trading halted, volatility trading pause 03/24/21 Canaccord Regeneron trial shows positive results against COVID-variants, says Canaccord 03/23/21 Piper Sandler Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler 03/11/21 Evercore ISI Kodiak Sciences initiated with an Outperform at Evercore ISI 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 03/24/21 BMO Capital AbCellera price target lowered to $59 from $61 at BMO Capital 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho 03/16/21 Mizuho Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab 03/15/21 JPMorgan Eli Lilly Alzheimer's data more mixed than expected, says JPMorgan 03/08/21 BofA Gartner added to US 1 List, Bristol-Myers removed at BofA 02/12/21 Morgan Stanley Amgen court decision may have readthrough for Gilead, says Morgan Stanley 02/02/21 BTIG Prothena upgraded to Buy at BTIG on birtamimab 'revival' 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair 02/23/21 B. Riley B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' ARQT Arcutis Biotherapeutics 02/02/21 Truist Arcutis Biotherapeutics price target raised to $48 from $38 at Truist 02/01/21 Cowen Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen 01/28/21 JonesTrading Arcutis Biotherapeutics initiated with a Buy at JonesTrading 11/09/20 Goldman Sachs Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs 02/10/21 SVB Leerink Incyte downgraded to Market Perform from Outperform at SVB Leerink 01/07/21 Truist Incyte initiated with a Buy at Truist 01/07/21 Truist Incyte initiated with a Buy at Truist 01/04/21 Guggenheim Incyte upgraded to Buy from Neutral at Guggenheim ACRS Aclaris Therapeutics 03/04/21 SVB Leerink Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink 02/02/21 Cantor Fitzgerald Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald 01/19/21 William Blair Aclaris has potential in range of 'blockbuster indications,' says William Blair 02/02/21 H.C. Wainwright BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright 12/07/20 H.C. Wainwright BiomX initiated with a Buy at H.C. Wainwright 10/05/20 H.C. Wainwright VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright 03/04/21 VYNE Therapeutics reports Q4 adjusted EPS (43c) , consensus (53c) 11/05/20 VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 02/09/21 Incyte reports Q4 EPS 93c, consensus 75c 02/08/21 Notable companies reporting before tomorrow's open 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 ARQT Arcutis Biotherapeutics 02/16/21 Arcutis Biotherapeutics reports Q4 EPS (79c), consensus (88c) 11/05/20 Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c) ACRS Aclaris Therapeutics 02/25/21 Aclaris Therapeutics reports Q4 EPS (30c), consensus (27c) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c)